9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
1 citations,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
20 citations,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
78 citations,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.